Dermira, Inc.
Eli Lilly and Company is a global medicine company dedicated to turning science into healing. With nearly 150 years of experience, Lilly focuses on disease areas such as Alzheimer's, cancer, diabetes, and obesity, striving to improve lives through innovative medicines and partnerships. The company emphasizes health, access, and scientific advancement, actively engaging in community support, research, and collaborations to address significant health challenges worldwide.
Industries
Nr. of Employees
medium (51-250)
Patents
Synthetic process for preparing 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate
US-9745277-B2
View Details
Synthetic process for preparing 2-((2-ethoxy-2-oxoethyl)(methyl)amino)-2-oxoethyl 5-tetradecyloxy)furan-2-carboxylate
US-9745277-B2
View DetailsProducts
PET imaging agents for brain pathology (amyloid and tau)
Regulatory-approved PET tracers used for estimating amyloid plaque density and imaging tau pathology to aid early diagnosis and monitor treatment effects.
PET imaging agents for brain pathology (amyloid and tau)
Regulatory-approved PET tracers used for estimating amyloid plaque density and imaging tau pathology to aid early diagnosis and monitor treatment effects.
Services
Strategic partnering, licensing, M&A evaluation and alliance/innovation management across therapeutic areas.
Investment, lab facilities and R&D services for early-stage companies, including lab incubation and R&D solutions.
Community-based screening, trial enrollment and decentralized study operations delivered via mobile research units.
Digital platform connecting patients to telehealth or in-person care with integrated pharmacy fulfillment and self-pay options.
Prospective supplier registration, supplier resources, mentorship and supplier diversity programs, plus invoicing and payment portals.
Medical information call center and online resources for patients and HCPs, including condition and product support and oncology patient financial/benefits assistance.
Strategic partnering, licensing, M&A evaluation and alliance/innovation management across therapeutic areas.
Investment, lab facilities and R&D services for early-stage companies, including lab incubation and R&D solutions.
Community-based screening, trial enrollment and decentralized study operations delivered via mobile research units.
Digital platform connecting patients to telehealth or in-person care with integrated pharmacy fulfillment and self-pay options.
Prospective supplier registration, supplier resources, mentorship and supplier diversity programs, plus invoicing and payment portals.
Medical information call center and online resources for patients and HCPs, including condition and product support and oncology patient financial/benefits assistance.
Expertise Areas
- Clinical trial management and decentralised trial operations
- Biologics and gene therapy development
- Radiopharmaceutical and diagnostic development
- Regulatory affairs and safety reporting
Key Technologies
- Positron emission tomography (PET) imaging agents
- Radioligand therapy methods
- AAV-based gene delivery
- Platform-driven oral small-molecule discovery
News & Updates
June 25, 2025 - Eli Lilly and Company announced that the U.S. FDA has approved a label update for Amyvid (florbetapir F 18 injection) for intravenous use. Amyvid is used for brain imaging to estimate amyloid plaque density in patients with cognitive impairment.
June 23, 2025 - The board of directors of Eli Lilly and Company has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock, payable on September 10, 2025.
June 22, 2025 - Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies.
June 21, 2025 - The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes. It also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40.
June 25, 2025 - Eli Lilly and Company announced that the U.S. FDA has approved a label update for Amyvid (florbetapir F 18 injection) for intravenous use. Amyvid is used for brain imaging to estimate amyloid plaque density in patients with cognitive impairment.
June 23, 2025 - The board of directors of Eli Lilly and Company has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock, payable on September 10, 2025.
June 22, 2025 - Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies.
June 21, 2025 - The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes. It also led to an average weight loss of 16.0 lbs (7.9%) at the highest dose by week 40.